following an abbreviated submission:
empagliflozin/linagliptin (Glyxambi®) is accepted for restricted use within NHSScotland.
Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus:
- To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control
- When already being treated with the free combination of empagliflozin and linagliptin
SMC restriction: Restricted to use in line with the previous SMC advice on empagliflozin and linagliptin.
In patients for whom this combination is appropriate, empagliflozin/linagliptin (Glyxambi®) offers a single tablet at a lower cost per dose compared with the individual components.
Download detailed advice163KB (PDF)
Medicine details
- Medicine name:
- empaglifozin linagliptin fixed-dose combination (Glyxambi)
- SMC ID:
- SMC1236/17
- Indication:
Indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control when already being treated with the free combination of empagliflozin and linagliptin
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 12 August 2019